Cobra inks agreement with Algeta ASA
October 2012

OSLO, Norway—Algeta ASA and Cobra Biologics Ltd have inked a contract manufacturing partnership agreement for Algeta's fourth Targeted Thorium Conjugate (TTC) program, which will focus on developing an undisclosed monoclonal antibody that is highly selective for a cell surface target on hematological cancer cells. Per the agreement, Cobra will provide cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP production. Cobra's maxXpress service combines the UCOE protein-expression technology with its cell line development team and the Cello robotic clone selection system for rapid clone selection and production of the monoclonal antibody.
"Algeta's contract forms part of a very successful year where we are seeing significant expansion in our antibody contract manufacturing as customers see the advantages Cobra's comprehensive services provide," said Peter Coleman, CEO of Cobra Biologics.

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.